-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $315

Benzinga·11/13/2026 13:10:24
Listen to the news
Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $300 to $315.